Febuxostat: A review of its use in the treatment of hyperuricaemia in patients with gout

Drugs

Volumn 75, Issue 4, 2015, Pages 427-438

  Frampton, James E ^a  

^a Springer   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; BILIRUBIN; FEBUXOSTAT; URIC ACID; ANTIGOUT AGENT;

ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GOUT; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FUNCTION TEST; NAUSEA; RASH; REVIEW; SIDE EFFECT; TREATMENT DURATION; URIC ACID BLOOD LEVEL; METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; FEBUXOSTAT; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; TREATMENT OUTCOME;

EID: 84925485771     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0360-7     Document Type: Review

References (60)

1. Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013. doi: 10.1136/bmj.f5648.
2. Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res. 2013;75:1-4.
3. Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs. 2008;68(13):1865-74.
4. Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(6 Suppl):S1-8.
5. Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180-9.
6. Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol. 2014;10(5):747-58.
7. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271-83.
8. Cassagnol M, Saad M. Pharmacologic management of gout. US Pharm. 2013;38(3):22-6.
9. Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout - what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319-28.
10. Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014;40(2):375-87.
11. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24.
12. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-46.
13. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82.
14. Menarini International Operations Luxembourg S.A. Adenuric 80 mg film-coated tablets: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000777/WC500021812.pdf. Accessed 23 Oct 2014.
15. Takeda Pharmaceuticals America, Inc. ULORIC (febuxostat) tablet for oral use: US prescribing information. 2013. http://general.takedapharm.com/content/file.aspx?filetypecode=ULORICPI&cacheRandomizer=579232da-e46d-4387-95a2-8f36cce19d42. Accessed 28 Oct 2013.
16. Teijin Pharma Limited. Feburic®: full prescribing information. Tokyo: Teijin Pharma Limited; 2011.
17. Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503-18.
18. Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209-20.
19. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114.
20. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22-34.
21. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186/ar2978.
22. Saag KG, Becker MA, Whelton A, et al. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: a randomized controlled trial [abstract no. 1178]. Arthritis Rheum. 2013;65:S498-9.
23. Tsai M, Wu J-T, Gunawardhana L, et al. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. Int J Clin Pharmacol Ther. 2012;50(5):331-7.
24. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916-23.
25. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540-8.
26. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-61.
27. Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S19-26.
28. Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S35-43.
29. Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13-8.
30. Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679-86.
31. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188-94.
32. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >65 years of age. BMC Geriatr. 2012;12:11. doi: 10.1186/1471-2318-12-11.
33. Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7.
34. Becker MA, MacDonald PA, Hunt BJ, et al. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049-55.
35. Wells AF, MacDonald PA, Chefo S, et al. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012;13:15. doi: 10.1186/1471-2474-13-15.
36. Chohan S, Becker MA, MacDonald PA, et al. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res. 2012;64(2):256-61.
37. European Medicines Agency. CHMP assessment report for Adenuric. International Nonproprietary Name: febuxostat. Procedure no. EMEA/H/C/777. 2008. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/000777/WC500021815.pdf. Accessed 16 Oct 2014.
38. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-97.
39. Takeda. Phase 3, febuxostat, allopurinol and placebo-controlled study in gout subjects. (APEX) [ClinicalTrials.gov identifier NCT00174915]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://clinicaltrials.gov/ct2/show/results/NCT00174915. Accessed 23 Sept 2014.
40. Whelton A, MacDonald PA, Chefo S, et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106-14.
41. Whelton A, MacDonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
42. Grassi D, Pontremoli R, Bocale R, et al. Therapeutic approaches to chronic hyperuricemia and gout. High Blood Press Cardiovasc Prev. 2014;21(4):243-50.
43. Overman RA, Mandell BF, Deal CL. Use of uric lowering therapies within a large health care system. [abstract no. 1909]. Arthritis Rheum. 2012;64(Suppl 10):S811.
44. Hatoum H, Khanna D, Lin S-J, et al. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65-75.
45. Becker MA, Ye X, Akhras KS, et al. Comparing clinical characteristics and comorbidities of gout patients treated with allopurinol or febuxostat [abstract no. 1814]. Arthritis Rheum. 2012;64:S771-2.
46. Perez-Ruiz F, Herrero-Beites AM. Liver outcomes in gout patients treated with febuxostat and altered liver function tests [abstract no. 1987]. Arthritis Rheum. 2013;65:S847.
47. Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol. 2014;26(2):162-8.
48. MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.
49. White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14-20.
50. Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15(5):453-63.
51. Cuesta M, Perez Alcantara F, Brosa M. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Spain [abstract no. PSY28]. Value Health. 2012;15(7):A513.
52. Richette P, Doherty M, Pascual E, et al. Updated evidence-based recommendations for the management of gout [abstract no. SAT0531]. Ann Rheum Dis 2014;73(Suppl 2). doi: 10.1136/annrheumdis-2014-eular.5022.
53. Manara M, Bortoluzzi A, Favero M, et al. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo. 2013;65(1):4-21.
54. Spanish Society of Rheumatology (SER). Clinical practice guidelines for management of gout. 2013. http://www.ser.es/ArchivosDESCARGABLES/Guias-Paciente/GuipClinGot-1140226-EN.pdf. Accessed 9 Feb 2015.
55. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids. 2004;23(8-9):1111-6.
56. Khosravan R, Grabowski B, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88-102.
57. Takeda. Efficacy and safety of oral febuxostat in participants with gout (CONFIRMS) [ClinicalTrials.gov identifier NCT00430248]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://clinicaltrials.gov/ct2/show/results/NCT00430248. Accessed 22 Sept 2014.
58. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-35.
59. National Institute for Health and Care Excellence. Febuxostat for the management of hyperuricaemia in people with gout. NICE technology appraisal guidance 164. 2008. http://www.nice.org.uk/guidance/ta164/resources/guidance-febuxostat-for-the-management-of-hyperuricaemia-in-people-with-gout-pdf. Accessed 12 Nov 2014.
60. Scottish Medicines Consortium. Febuxostat 80 mg and 120 mg tablets (Adenuric®). SMC No. 637/10. 2010. http://www.scottishmedicines.org.uk/files/advice/febuxostat-Adenuric-FINAL-August-2010.pdf. Accessed 12 Nov 2014.